U.S. Stock Market Midday Update

Regencell Bioscience, up 24.43%, with increased trading volume. Based on recent important news:

1. On June 16, Regencell Bioscience conducted a 38-for-1 stock split, expanding the number of circulating shares, attracting retail investors and driving the stock price surge.

2. On June 17, Regencell Bioscience pre-market rose 45%, despite the company not yet being profitable, with its core therapy needing to pass FDA Phase III clinical trials, with a failure probability as high as 80%.

3. On June 18, only 6% of Regencell Bioscience's total share capital was in circulation, and the extremely low liquidity made the stock price highly susceptible to manipulation.

Stocks with High Trading Volume in the Industry

Eli Lilly, up 0.75%, with a trading volume of $168 million. Based on recent important news:

1. On July 21, analysts gave Eli Lilly a "Strong Buy" rating, expecting good results from its oral GLP-1 trials, pushing the stock price up 0.75%.

2. On July 22, Eli Lilly was not included in the list of five stocks recommended by top analysts; nevertheless, analysts still gave it a "Moderate Buy" rating, keeping the stock price stable.

3. On July 23, market expectations for Eli Lilly's upcoming Q2 earnings report were high, driving the stock price up.

Johnson & Johnson, down 0.17%, with increased trading volume. Based on recent key news:

1. On July 23, Johnson & Johnson announced that the European Commission approved Imbruvica as the first targeted therapy for certain previously untreated mantle cell lymphoma patients, causing the stock price to rise.

2. On July 22, Johnson & Johnson announced a strategic agreement with Pacira Biosciences to expand market coverage for early intervention products for knee osteoarthritis, leading to a rise in stock price.

3. On July 21, Johnson & Johnson released its earnings report, with global sales increasing by 5.8% and net profit rising by 18.2%, resulting in a stock price increase.

Novo Nordisk, up 3.37%, with a trading volume of $116 million. Based on recent important news:

1. On July 22, Novo Nordisk announced that its semaglutide injection received approval for a new indication for chronic kidney disease, becoming China's first GLP-1RA drug, pushing the stock price up 3.37%.

2. On July 21, Novo Nordisk signed a memorandum of cooperation with Ark to establish a new ecosystem for health management, enhancing market confidence.

3. On July 21, analysts pointed out Novo Nordisk's leading position in weight management and its strong product line, further boosting investor confidence.

Stocks with High Market Capitalization in the Industry

Novartis, up 0.12%, with increased trading volume. Based on recent important news:

1. On July 22, Berenberg analysts indicated that Novartis's growth may slow in the second half of the year due to the increasing impact of patent expirations, necessitating accelerated business development to offset generic drug erosion, causing slight fluctuations in the stock price

2. On July 22, Novartis collaborated with Analysis Group to conduct research showing the importance of health economics and outcomes research in the evaluation and accessibility process, which enhanced market confidence in the company's innovation capabilities.

3. On July 21, Novartis released its Q2 2025 financial report, and the market's adjustment of expectations for its financial performance led to slight fluctuations in its stock price